Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Gains from Sales and Divestitures (2023 - 2025)

SAB Biotherapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $16723.0 for Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures fell 26.36% year-over-year to $16723.0; the TTM value through Dec 2025 reached $16723.0, down 26.36%, while the annual FY2025 figure was $16723.0, 26.36% down from the prior year.
  • Gains from Sales and Divestitures reached $16723.0 in Q4 2025 per SABSW's latest filing, up from $12544.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $106250.0 in Q3 2023 to a low of $4182.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 3 years is $28826.5, with a median of $16723.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 94.42% in 2024, then soared 100.0% in 2025.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $12816.0 in 2023, then skyrocketed by 77.19% to $22709.0 in 2024, then dropped by 26.36% to $16723.0 in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Gains from Sales and Divestitures are $16723.0 (Q4 2025), $12544.0 (Q3 2025), and $8364.0 (Q2 2025).